Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection.
The safety of high-dose oseltamivir during treatment of 2009 H1N1 influenza A infection for critically ill patients is unknown. Here we report on a case patient with severe, delayed-onset neuropsychiatric symptoms after administration of high-dose oseltamivir. Clinicians should be vigilant to the possible increased risk of complications associated with high-dose oseltamivir therapy for 2009 H1N1 influenza A infection.
Nakamura
Kenta
K
School of Medicine, University of California, San Francisco, California, USA.
Schwartz
Brian S
BS
Lindegårdh
Niklas
N
Keh
Chris
C
Guglielmo
B Joseph
BJ
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D003221:Confusion / Q000139:chemically induced; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000628:therapy; D008297:Male; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D053139:Oseltamivir / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D014182:Transplantation, Autologous
D000998:Antiviral Agents; D053139:Oseltamivir